This page provides Regulatory news filings submitted by issuers listed on the BSX. Please note the BSX is not responsible for the content, accuracy or completeness of announcements filed by issuers and disclaims all liability for any loss arising from reliance on information contained within issuer announcements.

Hamilton, Bermuda – January 5, 2018 – In a filing with the Bermuda Stock Exchange (“BSX”), JazzPharmaceuticalsplc(Nasdaq:JAZZ)announced on January 2, 2018 thecompany will be webcastingitscorporate presentation at the36thAnnualJ.P.MorganHealthcareConferenceinSanFrancisco,CA. The full filing stated:

DUBLIN,January2,2018--JazzPharmaceuticalsplc(Nasdaq:JAZZ)todayannouncedthatthecompanywillbewebcastingitscorporatepresentationatthe36thAnnualJ.P.MorganHealthcareConferenceinSanFrancisco,CA.

 

BruceCozadd,chairmanandchiefexecutiveofficer,willprovideanoverviewofthecompanyandabusinessandfinancialupdateattheconferenceonMonday,January8,2018at9:30a.m.PST/5:30p.m.GMT

A liveaudiowebcastofthepresentationmaybeaccessedfrom theInvestorssectionoftheJazzPharmaceuticalswebsiteat www.jazzpharmaceuticals.com. Pleaseconnect tothe websiteprior tothe startofthepresentation toensureadequatetimefor anysoftwaredownloadsthatmaybenecessarytolistentothewebcast.

Anarchiveofthewebcastwillbeavailable foratleastone weekfollowingthepresentationontheInvestorssection ofthe company’swebsiteat www.jazzpharmaceuticals.com.

AboutJazzPharmaceuticals

JazzPharmaceuticalsplc(Nasdaq:JAZZ)isaninternationalbiopharmaceuticalcompanyfocusedonimprovingpatients’livesbyidentifying, developingandcommercializingmeaningfulproducts that addressunmet medicalneeds.The company hasa diverseportfolioofproductsandproductcandidateswith afocusin theareas ofsleepandhematology/oncology.Intheseareas, JazzPharmaceuticalsmarketsXyrem®(sodiumoxybate) oralsolution,Erwinaze®(asparaginaseErwiniachrysanthemi),Defitelio®(defibrotidesodium) andVyxeos™(daunorubicinand  cytarabine)liposomefor injectionin the U.S.andmarketsErwinase®andDefitelio®(defibrotide) incountriesoutsidetheU.S. For moreinformation, pleasevisitwww.jazzpharmaceuticals.com.

 

 

 

 

Jazz PharmaceuticalsContacts:

Investors:

KatheeLittrell

VicePresident, Investor RelationsIreland, +3531 6347887

U.S.,+16504962717

 

Media:

JacquelineKirby

VicePresident, CorporateAffairs&GovernmentRelationsIreland, +3531 697 2141

U.S.,+12158674910